Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading Volume Following Insider Buying Activity

Pulse Biosciences, Inc (NASDAQ:PLSE) shares saw an uptick in trading volume on Monday after an insider bought additional shares in the company. 771,664 shares were traded during trading, an increase of 150% from the previous session’s volume of 308,746 shares.The stock last traded at $20.2650 and had previously closed at $19.08.

Specifically, Director Robert W. Duggan purchased 660,233 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $19.69 per share, with a total value of $12,999,987.77. Following the purchase, the director directly owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. The trade was a 1.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paul A. Laviolette purchased 15,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $19.69 per share, for a total transaction of $295,350.00. Following the purchase, the chief executive officer directly owned 15,000 shares in the company, valued at approximately $295,350. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Analysts Set New Price Targets

Several brokerages have recently commented on PLSE. Oppenheimer reissued an “outperform” rating and set a $30.00 price target on shares of Pulse Biosciences in a research note on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Tuesday, April 21st. Mizuho set a $30.00 price objective on Pulse Biosciences in a research report on Friday, February 6th. Finally, Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Stock Performance

The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -21.78 and a beta of 1.63. The company has a 50-day moving average of $21.03 and a 200-day moving average of $17.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.25 million. As a group, analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Argo Wealth Advisory LLC acquired a new position in Pulse Biosciences in the 4th quarter valued at $387,000. Westside Investment Management Inc. raised its holdings in Pulse Biosciences by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 66,326 shares of the company’s stock valued at $911,000 after acquiring an additional 1,886 shares during the last quarter. Quotient Wealth Partners LLC acquired a new position in Pulse Biosciences in the 4th quarter valued at $218,000. AlphaQuest LLC raised its holdings in Pulse Biosciences by 54.4% in the 3rd quarter. AlphaQuest LLC now owns 13,689 shares of the company’s stock valued at $242,000 after acquiring an additional 4,825 shares during the last quarter. Finally, KLP Kapitalforvaltning AS raised its holdings in Pulse Biosciences by 136.0% in the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after acquiring an additional 3,400 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.